Stocks and Investing Stocks and Investing
Fri, July 24, 2020
Thu, July 23, 2020
Wed, July 22, 2020
Tue, July 21, 2020

Charles Duncan Maintained (ACAD) at Buy with Decreased Target to $61 on, Jul 21st, 2020


Published on 2024-10-27 10:03:07 - WOPRAI, Charles Duncan
  Print publication without navigation


Charles Duncan of Cantor Fitzgerald, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Decreased Target from $63 to $61 on, Jul 21st, 2020.

Charles has made no other calls on ACAD in the last 4 months.



There are 3 other peers that have a rating on ACAD. Out of the 3 peers that are also analyzing ACAD, 0 agree with Charles's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Charles


  • Paul Matteis of "Stifel" Upgraded from Hold to Strong Buy and Increased Target to $71 on, Tuesday, July 7th, 2020
  • Chris Howerton of "Jefferies" Initiated at Strong Buy and Held Target at $60 on, Thursday, April 16th, 2020
  • Salveen Richter of "Goldman Sachs" Upgraded from Hold to Strong Buy and Increased Target to $72 on, Tuesday, March 31st, 2020